ZA200903953B - High protein concentration formulations containing mannitol - Google Patents

High protein concentration formulations containing mannitol

Info

Publication number
ZA200903953B
ZA200903953B ZA200903953A ZA200903953A ZA200903953B ZA 200903953 B ZA200903953 B ZA 200903953B ZA 200903953 A ZA200903953 A ZA 200903953A ZA 200903953 A ZA200903953 A ZA 200903953A ZA 200903953 B ZA200903953 B ZA 200903953B
Authority
ZA
South Africa
Prior art keywords
protein concentration
formulations containing
high protein
containing mannitol
concentration formulations
Prior art date
Application number
ZA200903953A
Other languages
English (en)
Inventor
David Christopher Sek
Kin Ho
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200903953B publication Critical patent/ZA200903953B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200903953A 2006-12-06 2009-06-05 High protein concentration formulations containing mannitol ZA200903953B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87352606P 2006-12-06 2006-12-06

Publications (1)

Publication Number Publication Date
ZA200903953B true ZA200903953B (en) 2010-03-31

Family

ID=39493053

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903953A ZA200903953B (en) 2006-12-06 2009-06-05 High protein concentration formulations containing mannitol

Country Status (13)

Country Link
US (1) US20080139792A1 (fr)
EP (1) EP2089001A2 (fr)
JP (1) JP2010512336A (fr)
KR (1) KR20090086632A (fr)
CN (1) CN101631535A (fr)
AU (1) AU2007329333A1 (fr)
BR (1) BRPI0720125A2 (fr)
CA (1) CA2671571A1 (fr)
IL (1) IL198977A0 (fr)
MX (1) MX2009005984A (fr)
RU (1) RU2009120200A (fr)
WO (1) WO2008070721A2 (fr)
ZA (1) ZA200903953B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
EP2288338A1 (fr) 2008-05-15 2011-03-02 Baxter International Inc. Formulations pharmaceutiques stables
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (fr) 2009-03-05 2010-09-10 Ablynx N.V. Nouveaux complexes dimères de liaison antigénique, méthodes d'obtention/non obtention et leurs utilisations
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
EP2473528B1 (fr) 2009-09-03 2014-12-03 Ablynx N.V. Formulations stables de polypeptides et leurs utilisations
WO2016202713A1 (fr) * 2015-06-15 2016-12-22 F. Hoffmann-La Roche Ag Procédé de congélation de solutions protéiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA902663B (en) * 1989-04-07 1991-12-24 Syntex Inc Interleukin-1 formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
WO2006014965A2 (fr) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Preparation pharmaceutique et processus

Also Published As

Publication number Publication date
JP2010512336A (ja) 2010-04-22
RU2009120200A (ru) 2011-01-20
US20080139792A1 (en) 2008-06-12
EP2089001A2 (fr) 2009-08-19
WO2008070721A2 (fr) 2008-06-12
IL198977A0 (en) 2010-02-17
CA2671571A1 (fr) 2008-06-12
KR20090086632A (ko) 2009-08-13
AU2007329333A1 (en) 2008-06-12
BRPI0720125A2 (pt) 2014-01-28
MX2009005984A (es) 2009-06-16
CN101631535A (zh) 2010-01-20
WO2008070721A3 (fr) 2008-09-18

Similar Documents

Publication Publication Date Title
HK1256288A1 (zh) 自緩衝蛋白製劑
ZA200903953B (en) High protein concentration formulations containing mannitol
IL192104A0 (en) Stable protein formulations
EP1988922A4 (fr) Formulations de protéines
GB2424581B (en) Formulations
IL184695A0 (en) Gastroresistant pharmaceutical formulations containing rifaximin
EP1863809A4 (fr) Pyrazolopyridines et analogues
HK1123188A1 (en) Liquid formulations
HRP20130109T1 (en) Caspofungin formulations
GB0504767D0 (en) Lipocalin protein
EP1909584A4 (fr) Formulations a base de prenylflavonoides
ZA200707654B (en) Formulations
IL192149A0 (en) Stable s-nitrosothiol formulations
GB0610140D0 (en) Protein stability
GB0625671D0 (en) Protein formulation
EP1951258A4 (fr) Formulations liquides
HUP0500813A2 (en) Pharmaceutical composition containing violaceae extract
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
GB0522113D0 (en) vWFA-domain containing proteins
SI1962886T1 (sl) Stabilne proteinske formulacije
GB0518878D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0526322D0 (en) Formulations